Low t therapy

Vujosevic et al (2013) reviewed the most important metabolic effects and clinical safety data of sub-threshold micropulse diode laser (D-MPL) in diabetic macular edema (DME).  The MPL treatment does not damage the retina and is selectively absorbed by the retinal pigment epithelium (RPE).  Micropulse diode laser stimulates secretion of different protective cytokines by the RPE.  No visible laser spots on the retina were noted on any fundus image modality in different studies, and there were no changes of the outer retina integrity.  Mean central retinal sensitivity (RS) increased in D-MPL group compared to standard Early Treatment Diabetic Retinopathy Study (ETDRS) photocoagulation group.  The authors concluded that MPL is a new, promising treatment option in DME, with both infrared and yellow wavelengths using the less aggressive duty cycle (5 %) and fixed power parameters.

Low t therapy

low t therapy


low t therapylow t therapylow t therapylow t therapylow t therapy